1. Chung, MK, Refaat, M, Shen, WK, et al. Atrial fibrillation. JACC Council Perspectives. J Am Coll Cardiol. 2020;75(14):1689–1713.
Google Scholar | Crossref | Medline2. Hagens, VE, Ranchor, AV, Van Sonderen, E, et al. Effect of rate or rhythm control on quality of life in persistent atrial fibrillation: results from the rate control versus electrical cardioversion (RACE) study. J Am Coll Cardiol. 2004;43(2):241–247.
Google Scholar | Crossref | Medline | ISI3. Mark, DB, Anstrom, KJ, Sheng, S, et al. Effect of catheter ablation vs medical therapy on quality of life among patients with atrial fibrillation: the CABANA randomized clinical trial. JAMA. 2019;321(13):1275–1285.
Google Scholar | Crossref | Medline4. Singh, B, Singh, S, Reda, D, et al. Amiodarone versus sotalol for atrial fibrillation. N Engl J Med. 2005;352(18):1861–1872.
Google Scholar | Crossref | Medline | ISI5. Anderson, JL, Stewart, JR, Perry, BA, et al. Oral flecainide acetate for treatment of ventricular arrhythmias in man. N Engl J Med. 1981;305(9):474–477.
Google Scholar | Crossref6. Anderson, JL, Gilbert, EM, Alpert, BL, et al. Prevention of symptomatic recurrences of paroxysmal atrial fibrillation in patients initially tolerating antiarrhythmic therapy. A multicenter, double-blind, crossover study of flecainide and placebo. Circulation. 1989;80(6):1557–1570.
Google Scholar | Crossref | Medline7. Anderson, JL, Platt, ML, Guarnieri, T, Fox, TL, Maser, MJ, Pritchett, ELC. Flecainide acetate for paroxysmal supraventricular tachyarrhythmias. Am J Cardiol. 1994;74(6):578–584.
Google Scholar | Crossref | Medline8. Henthorn, RW, Waldo, AL, Anderson, JL, et al. Flecainide for prevention of paroxysmal supraventricular tachycardia: a multicenter, double-blind, placebo-controlled study. Circulation. 1991;80(6):119–125.
Google Scholar | Crossref9. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators . Preliminary report: effect of encainide or flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med. 1989;321(6):406–412.
Google Scholar | Crossref | Medline | ISI10. Echt, DS, Liebson, PR, Mitchell, LB, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The cardiac arrhythmia suppression trial. N Engl J Med. 1991;324(12):781–788.
Google Scholar | Crossref | Medline | ISI11. Anderson, JL, Platia, EV, Hallstrom, A, et al. Interaction of baseline characteristics with the hazard of encainide, flecainide, and moricizine therapy in patients with myocardial infarction. A possible explanation for increased mortality in the cardiac arrhythmia suppression trial (CAST). Circulation. 1994;90(6):2843–2852.
Google Scholar | Crossref | Medline12. Akiyama, T, Pawitan, Y, Greenberg, H, Kuo, CS, Reynolds-Haertle, R. Increased risk of death and cardiac arrest from encainide and flecianide in patients after non-q-wave acute myocardial infarction in the cardiac arrhythmia suppression trial. Am J Cardiol. 1991;68(17):1551–1555.
Google Scholar | Crossref | Medline13. Lynch, JJ, DiCarlo, LA, Montgomery, DG, Lucchesi, B. Effects of flecainide acetate on ventricular tachyarrhythmia and fibrillation in dogs with recent myocardial infarction. Pharmacology. 1987;35(4):181–193.
Google Scholar | Crossref | Medline14. Hemmeryckx, B, Feng, Y, Frederix, L, et al. Evaluation of cardiac arrhythmic risks using a rabbit model of left ventricular systolic dysfunction. Eur J Pharmacol. 2018;832:145–155.
Google Scholar | Crossref | Medline15. Greenberg, HM, Dwyer, EM, Hochman, JS, Steinberg, JS, Echt, ES, Peters, R. Interactions of ischaemia and encainide/flecainide treatment: a proposed mechanism for the increased mortality in CAST. Br Heart J. 1995;74(6):631–635.
Google Scholar | Crossref | Medline16. January, CT, Wann, LS, Alpert, JS, et al. 2014 AHA/ACC/ HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2014;64(21):e1–e76.
Google Scholar | Crossref | Medline | ISI17. Kirchhof, P, Benussi, S, Kotecha, D, et al. 2016 ESC guidelines for the management of atrial fibrillation: developed in collaboration with EACTS. Eur J Cardiothorac Surg. 2016;50(5):e1–e88.
Google Scholar | Crossref | Medline18. Echt, DS, Ruskin, J. Use of flecainide for the treatment of atrial fibrillation. Am J Cardiol. 2020;125(7):1123–1133.
Google Scholar | Crossref | Medline19. Anderson, JL, Pratt, CM, Waldo, AL, Karagounis, L. Impact of the food and drug administration approval of flecainide and encainide on coronary artery disease mortality: putting deadly medicine to the test. Am J Cardiol. 1997;79(1):43–47.
Google Scholar | Crossref | Medline20. Romano, S, Fattore, I, Toscano, G, et al. Effectiveness and side effects of the treatment with propafenone and flecainide for recent-onset atrial fibrillation. Ital Heart J Suppl. 2001;2(1):41–45.
Google Scholar | Medline21. Webling, M . Meta-analysis of flecainide safety in patients with supraventricular arrhythmias. Arzneimittelforschung. 2002;52(7):507–514.
Google Scholar | Medline22. Aliot, E, Capucci, A, Crijns, HJ, Goette, A, Tamargo, J. Twenty-five years in the making: flecainide is safe and effective for the management of atrial fibrillation. Europace. 2011;13(2):161–173.
Google Scholar | Crossref | Medline23. Allen-LaPointe, NM, Dai, D, Thomas, L, Piccini, JP, Peterson, ED, Al-Khatib, S. Comparison of hospitalization rates among young atrial fibrillation patients receiving difference antiarrhythmic drugs. Circ Cardiovasc Qual Outcomes. 2015;8(3):292–300.
Google Scholar | Crossref | Medline24. Lafuente-Lafuente, C, Valembois, L, Bergmann, JF, Belmin, J. Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation. Cochrane Database Syst Rev. 2015;3:CD005049.
Google Scholar25. Bonora, A, Turcato, G, Franchi, E, et al. Efficacy and safety in pharmacological cardioversion of recent-onset atrial fibrillation: a propensity score matching to compare amiodarone vs class IC antiarrhythmic drugs. Intern Emerg Med. 2017;12(6):853–859.
Google Scholar | Crossref | Medline26. Friberg, L . Ventricular arrhythmia and death among atrial fibrillation patients using anti-arrhythmic drugs. Am Heart J. 2018;205:118–127.
Google Scholar | Crossref | Medline27. Markey, GC, Salter, N, Ryan, J. Intravenous flecainide for emergency department management of acute atrial fibrillation. J Emerg Med. 2018;54(3):320–327.
Google Scholar | Crossref | Medline28. Kipp, R, Askari, M, Fan, J, Field, ME, Turakhia, M. Real-world comparison of classes IC and III antiarrhythmic drugs as an initial rhythm control strategy in newly diagnosed atrial fibrillation: from the TREAT-AF study. JACC Clin Electrophysiol. 2019;5(2):231–241.
Google Scholar | Crossref | Medline29. Valembois, L, Audureau, E, Takeda, A, Belmin, J. Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation. Cochrane Database Syst Rev. 2019;9(9):CD005049.
Google Scholar | Medline30. Detrano, R, Guerci, AD, Carr, JJ, et al. Coronary calcium as a predictor of coronary events in four racial or ethnic groups. N Engl J Med. 2008;358(13):1336–1345.
Google Scholar | Crossref | Medline | ISI31. Blaha, MJ, Cainzos-Achirica, M, Greenland, P, et al. Role of coronary artery calcium score of zero and other negative risk markers for cardiovascular disease. The Multi-Ethnic Study of Atherosclerosis (MESA). Circulation. 2016;133(9):849–858.
Google Scholar | Crossref | Medline32. Greenland, P, Blaha, M, Budoff, MJ, Erbel, R, Watson, K. Coronary calcium score and cardiovascular risk. J Am Coll Cardiol. 2018;72(4):434–447.
Google Scholar | Crossref | Medline33. Mortensen, MB, Fuister, V, Mentendam, P, et-al. Negative risk markers for cardiovascular events in the elderly. J Am Coll Cardiol. 2019;74(1):1–11.
Google Scholar | Crossref | Medline34. Blaha, MJ, Blankenstein, R, Khurram, N. Coronary artery calcium scores of zero and establishing the concept of negative risk factors. J Am Coll Cardiol. 2019;74(1):12–14.
Google Scholar | Crossref | Medline35. Knight, S, Min, DB, Le, VT, et al. Implementation of a cardiac PET stress program: comparison of outcomes to the preceding SPECT era. JCI Insight. 2018;3(9):e120949.
Google Scholar | Crossref | Medline36. Anderson, JL, Le, VT, Min, DB, et al. Comparison of three atherosclerotic cardiovascular disease risk scores with and without coronary calcium for predicting revascularization and major adverse coronary events in symptomatic patients undergoing positron emission tomography-stress testing. Am J Cardiol. 2020;125(3):341–348.
Google Scholar | Crossref | Medline37. Anastasiou-Nana, MI, Anderson, JL, Stewart, JR, et al. Occurrence of exercise-induced wide-complex tachycardia during therapy with flecainide for complex ventricular arrhythmias: a probable pro-arrhythmic effect. Am Heart J. 1987;113(5):1071–1077.
Google Scholar | Crossref | Medline38. Morganroth, J, Horowitz, L. Flecainide: its proarrhythmic effect and expected changes on the surface electrocardiogram. Am J Cardiol. 1984;53:89b–94b.
Google Scholar | Crossref | Medline | ISI39. Nattel, S . Experimental evidence for proarrhythmic mechanisms of antiarrhythmic drugs. Cardiovasc Res. 1998;37(3):567–577.
Google Scholar | Crossref | Medline40. Salvage, SC, Chandrasekharan, KH, Jeevaratnam, K, et al. Multiple targets for flecainide action: implications for cardiac arrhythmogenesis. Br J Pharmacol. 2018;175(8):1260–1278.
Google Scholar | Crossref | Medline41. Maddox, TM, Stanislawski, MA, Grunwald, GK, et al. Non-obstructive coronary artery disease and risk of myocardial infarction. JAMA. 2014;312(17):1754–1763.
Google Scholar | Crossref | Medline42. Mortensen, M, Dzaye, O, Steffensen, F, et al. Impact of plaque burden versus stenosis on ischemic events in patients with coronary atherosclerosis. J Am Coll Cardiol. 2020;76(24):2803–2813.
Google Scholar | Crossref | Medline43. Akram, K, O’Donnell, RE, King, S, Superko, HR, Agatston, A, Voros, S. Influence of symptomatic status on the prevalence of obstructive coronary artery disease in patients with zero calcium score. Atherosclerosis. 2009;203(2):533–537.
Google Scholar | Crossref | Medline44. Budoff, MJ, Blankstein, R, Nasir, K, Blaha, MJ. Power of zero stronger than “soft” plaque. J Cardiovasc Comput Tomogr. 2020;14(3):279.
Google Scholar | Crossref | Medline45. Motoyama, S, Kondo, T, Masayoshi, S, et al. Miltislice computed tomographic characteristics of coronary lesions in acute coronary syndromes. J Am Coll Cardiol. 2007;50(4):319–326.
Google Scholar | Crossref | Medline | ISI46. Obaid, DR, Calvert, PA, Brown, A, et al. Coronary CT angiography features of ruptured and high-risk atherosclerotic plaques: correlation with intra-vascular ultrasound. J Cardiovasc Comput Tomogr. 2016;11(6):455–461.
Google Scholar | Crossref47. Le, VT, Knight, S, Min, DB, et al. Absence of coronary artery calcium during positron emission tomography stress testing in patients without known coronary artery disease identifies individuals with very low risk of cardiac events. Circ Cardiovasc Imaging. 2020;13(1):e009907.
Google Scholar | Crossref | Medline